Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Acute Myeloid Leukemia with t(6;11)(q27;q23.3); MLLT4-KMT2A — Survival · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm
Leukemia
Acute Leukemia
Acute Myeloid Leukemia
Acute Myeloid Leukemia with Genetic Abnormalities
Acute Myeloid Leukemia with KMT2A Rearrangement
Acute Myeloid Leukemia with a Variant KMT2A Rearrangement
Acute Myeloid Leukemia with t(6;11)(q27;q23.3); MLLT4-KMT2A

Molecular Subtype

Acute Myeloid Leukemia with t(6;11)(q27;q23.3); MLLT4-KMT2A

CI-CAN-00009315Explore in graph →

Hematologic

NCIt: C132105

Overview
Statistics
Survival
Genomics
Variants & evidence
Drugs
Trials
Research
Rankings
Sources & provenance

Survival

Population survival

Data not yet available

No survival observation is attached. Survival statistics require stage, staging system, diagnosis period, survival type and population — they are only imported with that full context (SEER, once credentials and terms are settled).

What CancerIndex knows

Statistics tab
Methodology: 5-year relative survival